GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys

Brain Research

Volumn 817, Issue 1-2, 1999, Pages 163-171

  Gerhardt, Greg A ^a   Cass, Wayne A ^b   Huettl, Peter ^a   Brock, Scot ^a   Zhang, Zhiming ^b   Gash, Don M ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Dopamine; Microdialysis; Monkey; Parkinson's disease; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DEXAMPHETAMINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; FEMALE; LOCOMOTION; MICRODIALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RHESUS MONKEY; STEREOTAXIS; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BASAL METABOLISM; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE AGENTS; FEMALE; FUNCTIONAL LATERALITY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID; MACACA MULATTA; MICRODIALYSIS; MPTP POISONING; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PUTAMEN; SUBSTANTIA NIGRA;

EID: 0033616388     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01244-X     Document Type: Article

References (41)

1. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39:1986;7-16.
2. Bernheimer H., Birkmayer W., Horynkiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J. Neurol. Sci. 20:1973;415-455.
3. Bjorklund A., Lindvall O. Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res. 83:1975;531-537.
4. Bowenkamp K.E., David D., Lapchak P.L., Henry M.A., Granholm A.C., Hoffer B.J., Mahalik T.J. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat - A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp. Brain Res. 111:1996;1-7.
5. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., Granholm A.C. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. Journal of Comparative Neurology. 355:1995;479-489.
6. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 80:1983;4546-4550.
7. Carman L.S., Gage F.H., Shults C.W. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res. 553:1991;275-283.
8. Cheramy A., Leviel V., Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature. 289:1981;537-542. (Review).
9. Church W.H., Justice J.B. Rapid sampling and determination of extracellular dopamine in vivo. Anal. Chem. 59:1987;712-716.
10. Gash D.M., Zhang Z., Cass W.A., Ovadia A., Simmerman L., Martin D., Russell D., Collins F., Hoffer B.J., Gerhardt G.A. Morphological and functional effects of intranigrally administered GDNF in normal Rhesus monkeys. Journal of Comparative Neurology. 363:1995;345-358.
11. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380:1996;252-255.
12. Gerhardt G.A., Cass W.A., Hudson J., Henson M., Zhang Z., Ovadia A., Hoffer B.J., Gash D.M. In vivo electrochemical studies of dopamine overflow and clearance in the striatum of normal and MPTP-treated Rhesus monkeys. J. Neurochem. 66:1996;579-588.
13. Hall M.A., Hoffer B.J., Gerhardt G.A. Rapid and sensitive determination of catecholamines in small tissue samples by high pressure liquid chromatography coupled with dual-electrode coulometric electrochemical detection. LC/GC. 7:1989;258-265.
14. Heeringa M.J., Abercrombie E.D. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J. Neurochem. 65:1995;192-200.
15. Hoehn M.M., Yahr M.D. Parkinsonism: onset progression and mortality. Neurology. 17:1967;427-442.
16. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.F., Gerhardt G.A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:1994;107-111.
17. Hoffman A.F., van Horne C.G., Eken S., Hoffer B.J., Gerhardt G.A. In vivo microdialysis studies of somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF. Exp. Neurol. 147:1997;130-141.
18. T. Hokfelt, A. Martensson, A. Bjorklund, S. Kleinau, M. Goldstein, Distributional maps of tyrosine-hydroxylase-immunoreactive neurons in the rat brain, in: A. Bjorklund, T. Hokfelt (Eds.), Handbook of Chemical Neuroanatomy, Elsevier, New York, 1984, pp. 387-406.
19. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34.
20. O. Hornykiewicz, Neurochemical pathology and pharmacology of brain dopamine and acetylcholine: rational basis for the current drug treatment of parkinsonism, in: F. Plum (Ed.), Recent Advances in Neurology, Vol. 6, Davis, Philadelphia, 1970.
21. Hudson J.L., van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., Hoffer B.J., Gerhardt G.A. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626:1993;167-174.
22. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv. Neurol. 45:1986;1-18.
23. Kurlan R., Kim M.H., Gash D.M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov. Disord. 6:1991;111-118.
24. 125I ]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection Brain Res. 789:1998;9-22.
25. Leenders K.L., Salmon E.P., Tyrrell P., Perani D., Brooks D.J., Sager H., Jones T., Marsden C.D., Frackowiak R.S. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch. Neurol. 47:1990;1290-1298.
26. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132. (see comments).
27. Lin L.F., Zhang T.J., Collins F., Armes L.G. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem. 63:1994;758-768.
28. Moghaddam B., Berridge C.W., Goldman-Rakic P.S., Bunney B.S., Roth R.H. In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse. 13:1993;215-222.
29. Orosz D., Bennett J.P. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the 'hemiparkinsonian' rat. Exp. Neurol. 115:1992;388-393.
30. Ovadia A., Zhang Z., Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging. 16(6):1995;931-937.
31. Robertson G.S., Damsma G., Fibiger H.C. Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J. Neurosci. 11:1991;2209-2216.
32. Robertson G.S., Robertson H.A. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci. 9:1989;3326-3331.
33. Rollema H., Alexander G.M., Grothusen J.R., Matos F., Castagnoli N. Jr. Comparison of the effects of intracerebrally administered MPP+ (1-methyl-4-phenylpyridinium) in three species: microdialysis of dopamine and metabolites in mouse, rat and monkey striatum. Neurosci. Lett. 106:1989;275-281.
34. Santiago M., Westerink B.H. Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J. Neurochem. 57:1991;738-747.
35. Saunders R.C., Kolachana B.S., Weinberger D.R. Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: an in vivo microdialysis study. Exp. Brain Res. 98:1994;44-52.
36. Skirboll S., Wang J., Mefford I., Hsiao J., Bankiewicz K.S. In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Exp. Neurol. 110:1990;187-193.
37. Smith R.D., Zhang Z., Kurlan R., McDermott M., Gash D.M. Developing a stable bilateral model of parkinsonism in Rhesus monkeys. Neuroscience. 52:1993;7-16.
38. Tomac A., Widenfalk J., Lin L.F., Kohno T., Ebendal T., Hoffer B.J., Olson L. Retrograde axonal transport of GDNF in the adult nigrostriatal system supports a trophic role in the adult. PNAS (USA). 92:1995;8274-8278.
39. Tseng J.L., Baetge E.E., Zurn A.D., Aebischer P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17:1997;325-333.
40. Wang J., Skirboll S., Aigner T.G., Saunders R.C., Hsiao J., Bankiewicz K.S. Methodology for microdialysis of neostriatum in hemiparkinsonian nonhuman primates. Exp. Neurol. 110:1990;181-186.
41. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 12(7):1990;290-296.